ArticleJournal of asthma and allergy2009
Ciclesonide: a safe and effective inhaled corticosteroid for the treatment of asthma.
Article in Journal of asthma and allergy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 21 citations in OpenAlex.
- Unravelling the Mysteries of the Sonic Hedgehog Pathway in Cancer Stem Cells: Activity, Crosstalk and Regulation.Current issues in molecular biology · 2024Review
- Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.Medicinal research reviews · 2021Review
- Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses.Advances in experimental medicine and biology · 2021Review
- The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.Medicinal research reviews · 2021Review
- Efficacy and Safety of Inhaled Ciclesonide in Treating Patients With Asymptomatic or Mild COVID-19 in the RACCO Trial: Protocol for a Multicenter, Open-label, Randomized Controlled Trial.JMIR research protocols · 2020Article
- Drug Discovery Strategies for SARS-CoV-2.The Journal of pharmacology and experimental therapeutics · 2020Review
- Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.Antimicrobial agents and chemotherapy · 2020Article
- Major ongoing clinical trials for COVID-19 treatment and studies currently being conducted or scheduled in Japan.Global health & medicine · 2020Review
- Inhalational Ciclesonide found beneficial in prevention of fat embolism syndrome and improvement of hypoxia in isolated skeletal trauma victims.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ciclesonide is a novel inhaled corticosteroid used in the continuous treatment of mild-to-severe asthma. Its formulation and mechanism of action yield a low oral and systemic bioavailability, and high pulmonary deposition. In multiple clinical trials, ciclesonide is at least as effective as either fluticasone propionate or budesonide at symptom control, while in many cases having improved safety outcomes and tolerability. The improved safety and comparable efficacy profiles of ciclesonide demonstrated in current studies could potentially yield a treatment option that may lead to improved adherence and outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.